We are live on ! Find out more
RM

RP Management Portfolio holdings

AUM $139M
1-Year Est. Return 37.98%
This Fund
S&P 500
This Quarter Est. Return
+16.06%
1 Year Est. Return
-37.98%
3 Year Est. Return
+207.8%
5 Year Est. Return
+1,098.05%
10 Year Est. Return
–
AUM
$326M
AUM Growth
-$341M
Cap. Flow
-$372M
Cap. Flow %
-114.08%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
1
Reduced
–
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$372M

Sector Composition

Rank Sector Weight
1 Healthcare 91.64%
2 Miscellaneous 8.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHVN
1
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$181M 55.51%
2,111,111
– –
EPZM
2
DELISTED
Epizyme, Inc
EPZM
$99.5M 30.54%
9,166,667
– –
EPZM
3
CALL
DELISTED
Epizyme, Inc
EPZM
$27.3M 8.36%
2,509,321
+9,321
+0.4% +$115K
CYTK icon
4
Cytokinetics
CYTK
$10.8B
$18.2M 5.58%
875,656
– –
VIRX
5
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$26K 0.01%
37,005
– –
IMMU
6
DELISTED
Immunomedics Inc
IMMU
– –
-4,373,178
Closed -$372M

Similar funds

PC
Paradoxiom Capital Stamford, Connecticut $154M AUM
LA
LPF Advisors Sarasota, Florida $122M AUM 3.12% 1-Year Est. Return
TP
Thunderbird Partners London, United Kingdom $113M AUM 8.51% 1-Year Est. Return
SC
Serenity Capital Palo Alto, California $167M AUM
MADFP
Michael A Dubis Financial Planning Middleton, Wisconsin $103M AUM
RM
RCF Management Denver, Colorado $103M AUM
NC
Napatree Capital Westerly, Rhode Island $178M AUM 8.09% 1-Year Est. Return
GWA
GGM Wealth Advisors Baltimore, Maryland $180M AUM 10.57% 1-Year Est. Return

RP Management's Q4 2020 Portfolio in Review

As of Q4 2020, RP Management held 6 positions worth $326M, down 51% from $667M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

RP Management withdrew a net $372M in Q4 2020, closing 1 position. Its most notable exit was Immunomedics Inc, an estimated $372M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 96% a quarter earlier, followed by Miscellaneous.

  • RP Management fully exited Immunomedics Inc in Q4 2020, selling an estimated $372M.
  • RP Management's ten largest holdings make up 100% of its $326M portfolio in Q4 2020.
  • RP Management opened 0 new positions and closed 1 in Q4 2020.
  • RP Management's portfolio value fell 51% quarter-over-quarter to $326M.

Based on RP Management's 13F filing for Q4 2020, filed 16 Feb 2021.